Literature DB >> 8878424

Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection.

Y Jin1, H C Dietz, R A Montgomery, W R Bell, I McIntosh, B Coller, P F Bray.   

Abstract

Glanzmann thrombasthenia (GT), an autosomal recessive bleeding disorder, results from abnormalities in the platelet fibrinogen receptor, GP(IIb)-IIIa (integrin alpha(IIb)beta3). A patient with GT was identified as homozygous for a G-->A mutation 6 bp upstream of the GP(IIIa) exon 9 splice donor site. Patient platelet GP(IIIa) transcripts lacked exon 9 despite normal DNA sequence in all of the cis-acting sequences known to regulate splice site selection. In vitro analysis of transcripts generated from mini-gene constructs demonstrated that exon skipping occurred only when the G-->A mutation was cis to a polymorphism 116 bp upstream, providing precedence that two sequence variations in the same exon which do not alter consensus splice sites and do not generate missense or nonsense mutations, can affect splice site selection. The mutant transcript resulted from utilization of a cryptic splice acceptor site and returned the open reading frame. These data support the hypothesis that pre-mRNA secondary structure and allelic sequence variants can influence splicing and provide new insight into the regulated control of RNA processing. In addition, haplotype analysis suggested that the patient has two identical copies of chromosome 17. Markers studied on three other chromosomes suggested this finding was not due to consanguinity. The restricted phenotype in this patient may provide information regarding the expression of potentially imprinted genes on chromosome 17.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878424      PMCID: PMC507612          DOI: 10.1172/JCI118973

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

Review 1.  Integrins: versatility, modulation, and signaling in cell adhesion.

Authors:  R O Hynes
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

2.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 3.  Splicing of messenger RNA precursors.

Authors:  R A Padgett; P J Grabowski; M M Konarska; S Seiler; P A Sharp
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

4.  Fibrinogen-binding properties of the human platelet glycoprotein IIb-=IIIa complex: a study using crossed-radioimmunoelectrophoresis.

Authors:  G O Gogstad; F Brosstad; M B Krutnes; I Hagen; N O Solum
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

5.  A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.

Authors:  B S Coller; E I Peerschke; L E Scudder; C A Sullivan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

6.  An algorithm for the display of nucleic acid secondary structure.

Authors:  G Lapalme; R J Cedergren; D Sankoff
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

7.  Severe Silver-Russell syndrome and translocation (17;20) (q25;q13)

Authors:  M L Ramírez-Dueñas; C Medina; R Ocampo-Campos; H Rivera
Journal:  Clin Genet       Date:  1992-01       Impact factor: 4.438

8.  Mutations which alter splicing in the human hypoxanthine-guanine phosphoribosyltransferase gene.

Authors:  H Steingrimsdottir; G Rowley; G Dorado; J Cole; A R Lehmann
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

9.  Molecular basis for Glanzmann's thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex.

Authors:  A Kato; K Yamamoto; S Miyazaki; S M Jung; M Moroi; N Aoki
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

10.  Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody.

Authors:  J S Bennett; J A Hoxie; S F Leitman; G Vilaire; D B Cines
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

View more
  18 in total

Review 1.  Demystified...adhesion molecule deficiencies.

Authors:  D Inwald; E G Davies; N Klein
Journal:  Mol Pathol       Date:  2001-02

2.  The ratio of maternal to paternal UPD associated with recessive diseases.

Authors:  Angela M Vianna-Morgante
Journal:  Hum Genet       Date:  2005-05-14       Impact factor: 4.132

3.  Study of V1a vasopressin receptor gene single nucleotide polymorphisms in platelet vasopressin responsiveness.

Authors:  Kazi N Hasan; Masaru Shoji; Shoji Tsutaya; Ryoko Kudo; Eriko Matsuda; Junko Saito; Tokihisa Kimura; Minoru Yasujima
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 4.  The regulation of splice-site selection, and its role in human disease.

Authors:  T A Cooper; W Mattox
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

5.  Sodium Butyrate and Valproic Acid as Splicing Restoring Agents in Erythroid Cells of β-Thalassemic Patients.

Authors:  Mahmoud Shekari Khaniani; Mahdieh Tagizadeh; Abbasali Hosseinpour Feizi; Sima Mansoori Derakhshan
Journal:  Iran J Biotechnol       Date:  2016-03       Impact factor: 1.671

6.  Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant?

Authors:  Z Karaca; S Taheri; F Tanriverdi; K Unluhizarci; F Kelestimur
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

7.  Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy.

Authors:  N Shiga; Y Takeshima; H Sakamoto; K Inoue; Y Yokota; M Yokoyama; M Matsuo
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

8.  Treatment of spinal muscular atrophy by sodium butyrate.

Authors:  J G Chang; H M Hsieh-Li; Y J Jong; N M Wang; C H Tsai; H Li
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

9.  Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.

Authors:  Xiying Shao; Lei Luo; Yong Guo; Xiaohong Xu; Dehou Deng; Jianguo Feng; Yuheng Ding; Hanzhou Mou; Ping Huang; Lei Shi; Yuan Huang; Weiwu Ye; Caijin Lou; Zhanhong Chen; Yabing Zheng; Xiaojia Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

10.  GSK3beta is a negative regulator of platelet function and thrombosis.

Authors:  Dongjun Li; Shelley August; Donna S Woulfe
Journal:  Blood       Date:  2008-01-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.